Browse ZFYVE16

Summary
SymbolZFYVE16
Namezinc finger, FYVE domain containing 16
Aliases KIAA0305; PPP1R69; endofin; protein phosphatase 1, regulatory subunit 69; endosome-associated FYVE-domain pr ......
Chromosomal Location5q14.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Cytoplasm Early endosome membrane Peripheral membrane protein Note=Localized to early endosomes. Membrane-associated, probably via its association with phosphatidylinositol 3-phosphate (PI3P).
Domain PF11979 Domain of unknown function (DUF3480)
PF01363 FYVE zinc finger
Function

May be involved in regulating membrane trafficking in the endosomal pathway. Overexpression induces endosome aggregation. Required to target TOM1 to endosomes.

> Gene Ontology
 
Biological Process GO:0006622 protein targeting to lysosome
GO:0006623 protein targeting to vacuole
GO:0007034 vacuolar transport
GO:0007041 lysosomal transport
GO:0007178 transmembrane receptor protein serine/threonine kinase signaling pathway
GO:0016050 vesicle organization
GO:0016197 endosomal transport
GO:0030100 regulation of endocytosis
GO:0030509 BMP signaling pathway
GO:0060627 regulation of vesicle-mediated transport
GO:0061462 protein localization to lysosome
GO:0071772 response to BMP
GO:0071773 cellular response to BMP stimulus
GO:0072665 protein localization to vacuole
GO:0072666 establishment of protein localization to vacuole
Molecular Function GO:0005543 phospholipid binding
GO:0005545 1-phosphatidylinositol binding
GO:0005547 phosphatidylinositol-3,4,5-trisphosphate binding
GO:0008565 protein transporter activity
GO:0035091 phosphatidylinositol binding
GO:1901981 phosphatidylinositol phosphate binding
Cellular Component GO:0005769 early endosome
GO:0010008 endosome membrane
GO:0031901 early endosome membrane
GO:0044440 endosomal part
> KEGG and Reactome Pathway
 
KEGG hsa04144 Endocytosis
hsa04350 TGF-beta signaling pathway
Reactome R-HSA-162582: Signal Transduction
R-HSA-201451: Signaling by BMP
Summary
SymbolZFYVE16
Namezinc finger, FYVE domain containing 16
Aliases KIAA0305; PPP1R69; endofin; protein phosphatase 1, regulatory subunit 69; endosome-associated FYVE-domain pr ......
Chromosomal Location5q14.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between ZFYVE16 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 

There is no record.

Summary
SymbolZFYVE16
Namezinc finger, FYVE domain containing 16
Aliases KIAA0305; PPP1R69; endofin; protein phosphatase 1, regulatory subunit 69; endosome-associated FYVE-domain pr ......
Chromosomal Location5q14.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of ZFYVE16 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolZFYVE16
Namezinc finger, FYVE domain containing 16
Aliases KIAA0305; PPP1R69; endofin; protein phosphatase 1, regulatory subunit 69; endosome-associated FYVE-domain pr ......
Chromosomal Location5q14.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of ZFYVE16 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)14120.4640.195
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)650.5340.758
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)870.4080.765
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 916-0.1380.738
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59-0.4510.841
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470.2580.928
729033130MelanomaallAnti-PD-1 (nivolumab) 2623-0.1320.754
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 1511-0.2020.92
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 1112-0.0120.996
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 480.0110.992
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 280.9980.491
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 68230-0.1350.0143
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of ZFYVE16 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14170001
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 277314.82.712.10.0439
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 275914.83.411.40.0746
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)211705.9-5.90.447
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)860001
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)131109.1-9.10.458
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 916012.5-12.50.52
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59022.2-22.20.505
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 38272.602.61
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22134.504.51
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16140001
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolZFYVE16
Namezinc finger, FYVE domain containing 16
Aliases KIAA0305; PPP1R69; endofin; protein phosphatase 1, regulatory subunit 69; endosome-associated FYVE-domain pr ......
Chromosomal Location5q14.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of ZFYVE16. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolZFYVE16
Namezinc finger, FYVE domain containing 16
Aliases KIAA0305; PPP1R69; endofin; protein phosphatase 1, regulatory subunit 69; endosome-associated FYVE-domain pr ......
Chromosomal Location5q14.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of ZFYVE16. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by ZFYVE16.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolZFYVE16
Namezinc finger, FYVE domain containing 16
Aliases KIAA0305; PPP1R69; endofin; protein phosphatase 1, regulatory subunit 69; endosome-associated FYVE-domain pr ......
Chromosomal Location5q14.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of ZFYVE16. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolZFYVE16
Namezinc finger, FYVE domain containing 16
Aliases KIAA0305; PPP1R69; endofin; protein phosphatase 1, regulatory subunit 69; endosome-associated FYVE-domain pr ......
Chromosomal Location5q14.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of ZFYVE16 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolZFYVE16
Namezinc finger, FYVE domain containing 16
Aliases KIAA0305; PPP1R69; endofin; protein phosphatase 1, regulatory subunit 69; endosome-associated FYVE-domain pr ......
Chromosomal Location5q14.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between ZFYVE16 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolZFYVE16
Namezinc finger, FYVE domain containing 16
Aliases KIAA0305; PPP1R69; endofin; protein phosphatase 1, regulatory subunit 69; endosome-associated FYVE-domain pr ......
Chromosomal Location5q14.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting ZFYVE16 collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.